Clinical Trial Update: Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept [Phase 4]

View source ↗

Summary

Phase 4 trial comparing ranibizumab or bevacizumab to aflibercept for wet age-related macular degeneration; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Avastin (bevacizumab)
• EYLEA (Aflibercept)
• Lucentis (ranibizumab)

Snippet

Sponsor: Rishi Singh | Conditions: Exudative Macular Degeneration | Phase 4 | Status: COMPLETED | Results posted: 2018-07-26